• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population.

作者信息

Gridelli Cesare, Rossi Antonio

机构信息

Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.

出版信息

J Thorac Dis. 2012 Apr 1;4(2):219-20. doi: 10.3978/j.issn.2072-1439.2012.03.03.

DOI:10.3978/j.issn.2072-1439.2012.03.03
PMID:22833832
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3378228/
Abstract
摘要

相似文献

1
EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population.厄洛替尼用于晚期非小细胞肺癌的一线Ⅲ期随机研究：厄洛替尼在欧洲人群中同样有效。
J Thorac Dis. 2012 Apr 1;4(2):219-20. doi: 10.3978/j.issn.2072-1439.2012.03.03.
2
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.厄洛替尼、阿法替尼和顺铂-培美曲塞用于美国晚期表皮生长因子受体（EGFR）突变阳性非小细胞肺癌一线治疗的成本效益和信息价值
Value Health. 2015 Sep;18(6):774-82. doi: 10.1016/j.jval.2015.04.008. Epub 2015 Jun 22.
3
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.表皮生长因子受体突变型晚期非小细胞肺癌一线使用厄洛替尼的经济学分析。
J Thorac Oncol. 2016 Jun;11(6):801-7. doi: 10.1016/j.jtho.2016.02.004. Epub 2016 Feb 18.
4
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.循环游离 DNA 中 EGFR L858R 突变与 EURTAC 试验生存的关联。
JAMA Oncol. 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257.
5
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.随机 III 期临床试验：厄洛替尼对比多西他赛在一线铂类双联化疗失败的晚期鳞状非小细胞肺癌患者中的应用，根据 VeriStrat 良好与 VeriStrat 不良进行分层。欧洲胸部肿瘤平台（ETOP） EMPHASIS-lung 试验。
J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.
6
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.厄洛替尼相关皮疹在接受 EURTAC 试验治疗的 EGFR 突变阳性非小细胞肺癌患者中的情况。
Future Oncol. 2015;11(3):421-9. doi: 10.2217/fon.14.269.
7
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.在德国晚期肺腺癌患者中基于表皮生长因子受体（EGFR）突变检测提供厄洛替尼的个体化一线治疗策略的成本效益
Pharmacoeconomics. 2015 Nov;33(11):1215-28. doi: 10.1007/s40273-015-0305-8.
8
First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view.晚期转移性非小细胞肺癌的一线和二线治疗：全球视角。
BMC Proc. 2008 Sep 24;2 Suppl 2(Suppl 2):S3. doi: 10.1186/1753-6561-2-s2-s3.
9
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.贝弗利：一项随机开放标签III期试验的原理与设计，该试验比较了贝伐单抗联合厄洛替尼与单纯厄洛替尼作为表皮生长因子受体（EGFR）突变的晚期非鳞状非小细胞肺癌患者一线治疗方案的疗效。
Clin Lung Cancer. 2016 Sep;17(5):461-465. doi: 10.1016/j.cllc.2016.04.001. Epub 2016 Apr 22.
10
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）一线治疗晚期非小细胞肺癌的成本效益分析。
J Med Econ. 2014 Aug;17(8):538-46. doi: 10.3111/13696998.2014.912987. Epub 2014 May 12.

引用本文的文献

1
Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis.循环肿瘤DNA（ctDNA）作为接受靶向治疗的非小细胞肺癌临床结局的预测指标：一项系统评价和荟萃分析
Cancers (Basel). 2023 Apr 23;15(9):2425. doi: 10.3390/cancers15092425.
2
Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.三种用于非小细胞肺癌靶向治疗的小分子药物的评估
Chin Med J (Engl). 2016 Feb 5;129(3):332-40. doi: 10.4103/0366-6999.174484.
3
The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib.吉非替尼治疗的非小细胞肺癌患者中肿瘤缩小率对无进展生存期的预后价值
Tuberc Respir Dis (Seoul). 2015 Oct;78(4):315-20. doi: 10.4046/trd.2015.78.4.315. Epub 2015 Oct 1.
4
Unusual presentation of metastatic sebaceous carcinoma and its response to chemotherapy: is genotyping a right answer for guiding chemotherapy in rare tumours?转移性皮脂腺癌的不寻常表现及其对化疗的反应：基因分型是指导罕见肿瘤化疗的正确答案吗？
Curr Oncol. 2015 Aug;22(4):e316-9. doi: 10.3747/co.22.2467.
5
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂治疗及挽救性化疗用于EGFR突变的老年肺腺癌患者
Oncologist. 2015 Jul;20(7):758-66. doi: 10.1634/theoncologist.2014-0352. Epub 2015 Jun 8.
6
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.美国国立综合癌症网络（NCCN）工作组报告：在多种生物标志物和靶向治疗时代设计临床试验
J Natl Compr Canc Netw. 2014 Nov;12(11):1629-49. doi: 10.6004/jnccn.2014.0161.
7
EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence.非小细胞肺癌细胞学和组织学样本的表皮生长因子受体（EGFR）突变检测：一项波兰单机构研究及欧洲发病率的系统综述
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2800-12. eCollection 2013.

本文引用的文献

1
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
2
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.厄洛替尼对比化疗用于治疗晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（OPTIMAL、CTONG-0802）：一项多中心、开放标签、随机、III 期研究。
Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23.
3
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.一项在既往化疗失败的晚期非小细胞肺癌患者中比较吉非替尼和厄洛替尼疗效的随机 II 期临床研究。
Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.
4
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.吉非替尼或化疗用于治疗具有突变型 EGFR 的非小细胞肺癌。
N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.
5
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者（WJTOG3405）：一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.